Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Overview Pacylex has a precision medicine solution for 19
Document related concepts
no text concepts found
Transcript
The Opportunity • Our first product is a precision medicine based patient selection biomarker & therapeutic combination targeting the NMT/myristoylation pathway • Lead candidate is a result of three generations of compounds, has structure-activity relationship information, is orally bioavailable, and has Pk/Pd data. IC50 below 10nM for recombinant human NMT1 with over 50 members of the series with IC50s of 20nM or less • Biomarker that confers the sensitivity to our drug is lost in 19 types of cancer at a prevalence that varies from 582%, the highest being in hematological malignancies. • Through a collaboration with an undisclosed pharmaceutical company (non-binding agreement), breadth of efficacy studies have shown promising results in multiple solid tumour models including small cell lung cancer • Multiple mouse efficacy studies show eradication of AML, Burkitts Lymphoma, and DLBCL xenograft tumours in mice with treatment • All applicable indications combined lead to a >1.1M biomarker screenings and >150K therapeutic candidate patients per year in North America – >$3.5B annual potential revenue Cancer patients that do not respond to current standards of care Luc Berthiaume, PhD Chief Executive Officer [email protected] Pacylex NMT screen Overview Pacylex has a precision medicine solution for 19 candidate cancer types: i) our predictive diagnostic test identifies cancer patient candidates for ii) our rationally designed small molecule inhibitor Team CEO & CSO Luc G. Berthiaume PhD CMO John Mackey, MD, FRCPC COO Ryan Heit, MSc, MBA Funding to date Grants - >$7,200,000 CAD Founder capital - $530,000 CAD Potential pharma partner breadth of efficacy studies - $650,000 USD in kind Project state Completed: Animal efficacy, PK/PD, Biomarker monoclonal antibody created Next steps: Animal safety studies, Regulatory filings, Phase I/IIa study Negative John Mackey, MD, FRCP Chief Medical Officer [email protected] Pacylex targeted chemotherapeutic Ryan Heit, MSc, MBA Chief Operating Officer [email protected]
